The carbonic anhydrase inhibitors, particularly acetazolamide (Diamox), have become a standard adjunct in the short-term management of the glaucomas since they were first evaluated by Becker,1 in 1954. There are now numerous reports in the literature which indicate that long-term therapy is effective with these compounds without any obvious ill effect on the ocular tissues. The greatest number of failures in long-term control of the glaucomas with carbonic anhydrase inhibitors to date have been due to the large proportion of sideeffects which have frequently necessitated cessation of therapy; only relatively few cases have become truly refractory. A number of newer carbonic anhydrase inhibitors are being evaluated in a search for a more powerful inhibitor with minimal side-effects in the dosage required.
Ethoxzolamide (Cardrase) is a new potent carbonic anhydrase inhibitor the use of which in ophthalmology has been reported on, particularly in the therapy of intraocular inflammation, by Gordon,
DRANCE SM. The Effects of Ethoxzolamide (Cardrase) on Intraocular Pressure. AMA Arch Ophthalmol. 1959;62(4):679–684. doi:10.1001/archopht.1959.04220040141020
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.